{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"Complete response rate was defined as the percentage of participants who achieved a complete response.","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"OG000","title":"Idelalisib + Rituximab"},{"description":"Placebo to match idelalisib administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"OG001","title":"Placebo + Rituximab"}],"paramType":"NUMBER","populationDescription":"ITT Analysis Set: randomized participants with treatment group designated according to initial randomization.","reportingStatus":"POSTED","timeFrame":"Up to 17 months","title":"Complete Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}